Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00824161).
- Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy: primary endpoint results,…
- Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.: primary endpoint results, effect estimate with…
- Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: primary endpoint…
- Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002): Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002): primary endpoint results,…
- Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05068752).
- Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01827371).
- Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10: Complete Statistical AnalysisIndependent statistical analysis of Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02329730).
- Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006): Complete Statistical AnalysisIndependent statistical analysis of Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED): Complete Statistical AnalysisIndependent statistical analysis of Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED):…
- Phase IIb Study of STA-2 in Patients With Chronic Stable Angina: Complete Statistical AnalysisIndependent statistical analysis of Phase IIb Study of STA-2 in Patients With Chronic Stable Angina: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma: Complete Statistical AnalysisIndependent statistical analysis of Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase IIB TL + YCWP + DC in Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase IIB TL + YCWP + DC in Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02301611).
- Phase III B in Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase III B in Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03123939).
- Phase III Cat-PAD Follow-on Study: Complete Statistical AnalysisIndependent statistical analysis of Phase III Cat-PAD Follow-on Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02040844).
- Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase III Study of MLN0002 (300 mg) in Treatment of Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size…
- Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase III Trial of Coenzyme Q10 in Mitochondrial Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase III Trial of Coenzyme Q10 in Mitochondrial Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00432744).
- Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase IIIb Study of APD421 in Combination as PONV Prophylaxis: Complete Statistical AnalysisIndependent statistical analysis of Phase IIIb Study of APD421 in Combination as PONV Prophylaxis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02337062).
- Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China: Complete Statistical AnalysisIndependent statistical analysis of Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib: Complete Statistical AnalysisIndependent statistical analysis of Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib: primary endpoint results, effect estimate with confidence…
- Phase l/II Study of Ruxolitinib for Acute Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase l/II Study of Ruxolitinib for Acute Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01251965).
- PHASE ProjectIndependent statistical analysis of Premenstrual Hormonal and Affective State Evaluation (PHASE) Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03862469).
- PHE-LEEPIndependent statistical analysis of Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phendimetrazine and Cocaine: Complete Statistical AnalysisIndependent statistical analysis of Phendimetrazine and Cocaine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02233647).
- Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel: Complete Statistical AnalysisIndependent statistical analysis of Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02217709).